Iterative Gaussian process screening discovers selective aurein-derived antifungal peptides
An uncertainty-aware Gaussian process regression workflow iteratively selected 23 synthetic α/β-peptide analogues for synthesis and measurements of fungal inhibition and human-red-blood-cell hemolysis. One lead, peptide 6-4, was a measured variant of an existing aurein-derived template and achieved a selectivity index of 57.1 (60.9 using the study’s finer MIC interval) versus 1.2 for aurein 1.2. Its high selectivity was driven by low hemolysis; the result is a specific peptide-design and assay contribution, not a new peptide scaffold or evidence of therapeutic efficacy. The ChemRxiv v1 result was posted on 2024-10-04; the peer-reviewed journal article followed in 2025.
Technology: Iterative uncertainty-aware Gaussian process regression using molecular descriptors and measured antifungal/hemolysis labels
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: Across six iterative rounds, uncertainty-aware Gaussian process regression selected 23 peptide variants for synthesis and antifungal/hemolysis assays. Lead 6-4 had a selectivity index of 57.1 (60.9 using the study’s finer MIC interval), versus 1.2 for aurein 1.2; the authors attribute the selectivity to reduced hemolysis.
- Still unknown: Peptide 6-4 modifies a known aurein-derived template. The result is a measured sequence and assay outcome, not evidence of a new scaffold or therapeutic efficacy. The version-specific first public result is the 2024 ChemRxiv preprint; the journal article followed in 2025.
- AI role: An uncertainty-aware Gaussian process regression model selected peptide variants for synthesis and assays, and measured outcomes were fed back into subsequent selection rounds.
Evidence sources: https://chemrxiv.org/engage/chemrxiv/article-details/67a7e4386dde43c9081bdfc1 · https://pubs.rsc.org/en/content/articlepdf/2025/sc/d4sc06689h · https://pubmed.ncbi.nlm.nih.gov/40028619/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary ChemRxiv version-history record and v2 manuscript; primary RSC indexed full article PDF, including sequence tables, Results, Methods and publication metadata; PubMed primary abstract/affiliation metadata..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.